Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.79+0.45%BTC$85,601.00-0.41%ETH$2,698.06-0.77%GOLD$4,194.40+0.17%OIL$89.74+0.34%
Smart Investors Daily
SID Premium
BioLineRx Ltd. logo

NASDAQ · BLRX

BioLineRx Ltd.

Healthcare · Biotechnology

$2.32

Down-$0.03 (-1.19%)

Updated Oct 6, 2026, 10:16 PM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
14.09M
P/E ratio
-1.61
Dividend yield
0.00%
52-week range
$2.15 – $4.56
Volume
20.26K
Avg. volume
34.05K

Price performance · BLRX

BLRX price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 5, 2026

BLRX closed at $2.32 after 20 trading sessions, down 10.42% for the selected period.

Last close
$2.32
Period change
-10.42%
Period low
$2.32
Period high
$2.60
Daily close
View OHLC price history
BLRX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 5, 2026$2.36$2.36$2.29$2.3220.26K
Oct 2, 2026$2.31$2.37$2.31$2.373.13K
Oct 1, 2026$2.32$2.3886$2.32$2.357.58K
Sep 30, 2026$2.36$2.395$2.30$2.3540.78K
Sep 29, 2026$2.41$2.495$2.36$2.3612.08K
Sep 28, 2026$2.50$2.50$2.41$2.4312.56K
Sep 25, 2026$2.49$2.60$2.49$2.609.89K
Sep 24, 2026$2.56$2.59$2.44$2.5211.54K
Sep 23, 2026$2.53$2.572$2.4503$2.5612.67K
Sep 22, 2026$2.48$2.5995$2.42$2.4310.35K
Sep 21, 2026$2.53$2.5843$2.4482$2.4817.13K
Sep 18, 2026$2.50$2.51$2.4401$2.4872.75K
Sep 17, 2026$2.63$2.63$2.43$2.5311.87K
Sep 16, 2026$2.52$2.54$2.476$2.484.35K
Sep 15, 2026$2.50$2.545$2.45$2.5229.11K
Sep 14, 2026$2.52$2.52$2.43$2.4321.21K
Sep 11, 2026$2.575$2.62$2.50$2.519.54K
Sep 10, 2026$2.53$2.63$2.52$2.56958.13K
Sep 9, 2026$2.59$2.59$2.53$2.557.74K
Sep 8, 2026$2.78$2.78$2.55$2.5919.85K

Latest BLRX news

The latest Smart Investors Daily articles mentioning BLRX.

Stock researchCompany · Overview

BLRX research

Overview

Company profile and research snapshot.

Company profile

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
BLRX recent ratings
DateFirmRatingTarget
Dec 16, 2020HC Wainwright & Co.Buy—
Aug 4, 2017OppenheimerOutperform—
May 18, 2017Maxim GroupBuy—
Feb 13, 2017Rodman & RenshawBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 10, 2026

BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, today announced that two abstracts featuring GLIX1 have been accepted for presentation, including one selected for oral presentation highlighting the preclinical efficacy of GLIX1 in orthotopic glioblastoma models, at the 21st Meeting of the Europe

Yahoo · Sep 1, 2026

BLRX: New GLIX1 Data Touts Synergies

By John Vandermosten, CFA NASDAQ: BLRX READ THE FULL BLRX RESEARCH REPORT BioLineRx Ltd. (NASDAQ: BLRX) reported second quarter 2026 financial and operational results in an August 31 st press release. For the quarter, it produced license revenues of $294,000 and a net loss of $4.3 million. The joint venture (JV) with Hemispherian, which is developing GLIX1, has begun enrolling the second of five

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By